2 news items
Quince Therapeutics Updates Pipeline Progress, Eyes Enrollment for Pivotal Phase 3 Trial in Ataxia-Telangiectasia, Reported Q1 EPS Loss of $(0.26), Cash Balance of $67.8M
QNCX
13 May 24
study.
Reported research and development (R&D) expenses of $3.7 million for the quarter ended March 31, 2024. R&D expenses
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
QNCX
13 May 24
.
Reported research and development (R&D) expenses of $3.7 million for the quarter ended
- Prev
- 1
- Next